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TITLE OF CASE Do not include “a case report” 
Levetiracetam-induced eosinophilic pneumonia  
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
Levetiracetam is widely regarded as a benign anti-epileptic drug, in contrast to older anti-epileptic 
medication. We report a case of eosinophilic pneumonia due to levetiracetam use in a 59-year old 
non-smoking woman with no previous respiratory history. Our patient presented with exertional 
breathlessness and marked desaturation on exertion. She displayed 'reverse bat-wing' infiltrates on 
her chest radiograph and peripheral eosinophilia on a complete blood count. Her symptoms, 
radiology and peripheral eosinophilia resolved completely with cessation of levetiracetam and a 
course of prednisolone. This is the first report of isolated eosinophilic pneumonia due to 
levetiracetam. Other reports of levetiracetam-induced eosinophilia describe drug rash, 
eosinophilia, and systemic symptoms (DRESS syndrome). Detection of pulmonary drug reactions 
requires a careful drug history and high index of suspicion. Identifying and reporting a causative 
agent is crucially important, as cessation of the drug is essential for resolution of the syndrome. 
 
BACKGROUND Why you think this case is important – why did you write it up? 
Levetiracetam is a relatively recently introduced anti-epileptic drug which functions by binding to 
synaptic vesicle protein (SV2A), thus reducing the rate of vesicle release1. It has been 
recommended by NICE as an alternative first-line treatment in focal and myoclonic seizures, as 
well as an adjunctive treatment for focal, generalised tonic clonic and myoclonic seizures2. 
Levetiracetam is growing in popularity as it is widely regarded as a benign anti-epileptic with 
comparatively few side effects and interactions, particularly when compared to older drugs such 
as carbamazepine. For example, levetiracetam is linked to cutaneous reactions in approximately 
1.7% of patients compared to 5-15% for phenytoin, carbamazepine, and phenobarbitone; and 8.3-
20% for lamotrigine3-5. Levetiracetam also appears to have a far lower incidence of the rarer but 
potentially very dangerous idiosyncratic reactions such as agranulocytosis and aplastic anaemia 
(carbamazepine, phenytoin), pancreatitis (carbamazepine, phenytoin), and hepatic failure 
(valproate, carbamazepine, phenytoin). Direct comparisons are difficult as levetiracetam was 
launched recently, and there are few blinded randomized control trials comparing anti-epileptics. 
This is the first known report of isolated eosinophilic pneumonia secondary to levetiracetam.  
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CASE PRESENTATION Presenting features, medical/social/family history 
A 59-year old non-smoking female presented with several weeks of exertional breathlessness and 
night sweats. She had been recently diagnosed with a meningioma and linked her symptoms to 
starting levetiracetam 8 weeks prior (as treatment for meningioma-related absence seizures). She 
did not have a cough, chest pain or any other previous medical history. Her physical examination 
was unremarkable other than peripheral oxygen saturations which dropped from 95% to 88% on 
exercise. There was no wheeze, rash, lymphadenopathy or angioedema.  
 
 
 
INVESTIGATIONS If relevant 
New eosinophilia (8.38x109/L) was the only abnormality on blood tests. Her chest radiograph 
(Fig.1AI) showed ‘reverse bat-wing’ infiltrates in an asymmetrical pattern (more marked on the 
right). Computed-tomography showed peripheral areas of consolidation (Fig.1B).  
 
 
DIFFERENTIAL DIAGNOSIS If relevant 
Eosinophilia can be defined as a raised eosinophil count of ≥0.5x109/L, with hypereosinophilia 
indicating severe eosinophilia (≥1.5x109/L) and hypereosinophilic syndrome describing 
hypereosinophilia occurring on at least 2 occasions with end-organ damage attributable to the 
eosinophilia. Eosinophilic pneumonias are a heterogeneous group of disorders characterised by 
eosinophilia and pulmonary infiltrates. In eosinophilic pneumonias, the eosinophilia can affect the 
peripheral blood and the lungs or be limited to the lungs. Eosinophilic pneumonias can be part of 
an underlying disorder (such as allergic broncho-pulmonary aspergillosis, autoimmune disorders 
e.g. eosinophilic granulomatosis with polyangiitis, infections, particularly of a parasitic nature, 
and malignancy) or they can primarily affect the lungs (acute eosinophilic pneumonia, chronic 
eosinophilic pneumonia, and drug-induced eosinophilic pneumonia).  
 
Our patient was a life-long resident of the United Kingdom with no recent travel history or 
symptoms to suggest parasitic infection. There was no history of weight loss, lymphadenopathy 
or any other abnormality in the full blood count (aside from eosinophilia) that would suggest an 
underlying malignancy. Levetiracetam was the only drug that had been recently started and our 
patient denied any over-the-counter medications or herbal supplements. The combination of 
temporally-linked symptoms, eosinophilia and suggestive radiology was felt to be highly 
characteristic of a drug reaction and therefore tissue biopsy was not sought. 
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TREATMENT If relevant  
 
Our patient was reasonably well, her eosinophilic pneumonia appeared to be clearly driven by the 
levetiracetam and she had a good support network at home. Therefore we felt that outpatient 
treatment was appropriate. The levetiracetam was stopped. As she had previously experienced 
meningioma-related seizures she was discussed with the neurosurgeons. Phenytoin was 
prescribed as a replacement anti-epileptic. As there was evidence of end-organ dysfunction (in the 
form of exertional desaturation) she was treated with a course of prednisolone, which was tapered 
off gradually over the next two months. 
 
OUTCOME AND FOLLOW-UP   
 
The patient was followed-up 12 days later. She had clinically improved but still had low-level 
eosinophilia (1.28x109/L). One month later her chest radiograph and eosinophil count (Fig.1AIII, 
1C) had normalised and she was symptom-free.  
 
DISCUSSION Include a very brief review of similar published cases  
 
The original clinical trials of levetiracetam reported accidental injury, asthenia, dizziness, 
headache, infection, nausea and somnolence as primary adverse reactions6. Interestingly none of 
them occurred more frequently than in placebo arms. Since then the most commonly reported side 
effects of levetiracetam are neuropsychiatric (in approximately 13% of adult patients); ranging 
from dizziness, somnolence, depression and hostility, to frank psychosis7. This is the first report 
of ‘stand-alone’ eosinophilic pneumonia due to levetiracetam. Other reports of levetiracetam-
induced eosinophilic syndromes describe drug rash, eosinophilia, and systemic symptoms 
(DRESS syndrome) with concomitant pulmonary infiltrates8-11.  
 
Antiepileptic drugs, in particular carbamazepine, phenytoin and phenobarbital, are the most 
common causes of drug-induced eosinophilia and DRESS; but allopurinol, antibiotics (especially 
sulphonamides), anti-malarials and NSAIDs have also been implicated12. DRESS is a delayed T-
cell mediated reaction and several causes have been proposed, including a genetic deficiency of 
drug-metabolizing enzymes, associations with specific human leucocyte antigens (HLAs) and 
possible reactivation of latent herpes viruses through drug-virus interactions13. Cross-reactions 
between phenytoin, carbamazepine, phenobarbitone and oxcarbazepine are common as they share 
a similar ‘aromatic’ structure14. Levetiracetam has a different structure, which may account for 
the low-incidence of cross-reactivity with other anti-epileptics. 
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Detection of pulmonary drug reactions and DRESS requires a careful history and high index of 
suspicion. The RegiSCAR scoring system has recently been developed to report and grade 
suspected DRESS cases as being ‘unlikely to be drug-associated’, ‘possible’, ‘probable’, or 
‘definite’15. Prompt recognition is crucial as the mortality associated with DRESS approaches 
10%12. Both pulmonary drug reactions and DRESS syndrome are managed by withdrawal of the 
offending agent and careful supportive treatment16. Corticosteroids are frequently used but 
evidence is limited. Helpful resources for information on drug-induced respiratory disease include 
the Pneumotox website17 and the U.S. Food and Drug Administration Medwatch programme18. 
The former is particularly user-friendly as it allows searching the database by individual drug 
names as well as by patterns of pulmonary disease. Reporting of drug reactions is critical to allow 
clinicians a complete view of the risk/benefit balance prior to recommending specific 
medications. 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
1. New eosinophilia (>0.5 x 109/L or 3% of leucocytes) should always raise the possibility of 
drug-induced syndromes. 
2. Detection of pulmonary drug reactions requires a careful history and high index of 
suspicion. The physician should enquire not only about prescribed medications but also 
over-the-counter remedies, herbal supplements and illicit drug use.  
3. Identifying and reporting a causative agent is important, as cessation of the agent is crucial 
for resolution of the pulmonary syndrome. 
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FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
Figure 1: 
A: Plain chest radiograph of the patient on admission (I), after levetiracetam cessation and 12 
days of prednisolone (II) and after levetiracetam cessation and 4 weeks of prednisolone (III). 
B: Selected computed-tomography slices (performed on initial diagnosis) showing patchy 
areas of ground-glass throughout the lung fields. 
C: Table showing eosinophil count before and throughout treatment.   
Figure 2:  
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Chemical structure of levetiracetam, phenytoin, carbamazepine and oxcarbazepine.  
 
 
 
 
 
PATIENT’S PERSPECTIVE Optional but strongly encouraged – this has to be written 
by the patient or next of kin 
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